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Protein glycosylation plays an important role in a multitude of
biological processes such as cell–cell recognition, growth,
differentiation, and cell death. It has been shown that specific
glycosylation changes are key in disease progression and can
have diagnostic value for a variety of disease types such as
cancer and inflammation. The complexity of carbohydrate
structures and their derivatives makes their study a real
challenge. Improving the isolation, separation, and character-
ization of carbohydrates and their glycoproteins is a subject of
increasing scientific interest. With the development of new
stationary phases and molecules that have affinity properties
for glycoproteins, the isolation and separation of these
compounds have advanced significantly. In addition to
detection with mass spectrometry, the microarray platform
has become an essential tool to characterize glycan structure
and to study glycosylation-related biological interactions, by
using probes as a means to interrogate the spotted or captured
glycosylated molecules on the arrays. Furthermore, the high-
throughput and reproducible nature of microarray platforms
have been highlighted by its extensive applications in the field
of biomarker validation, where a large number of samples must
be analyzed multiple times. This review covers a brief survey of
the other experimental methodologies that are currently being
developed and used to study glycosylation and emphasizes
methodologies that involve the use of microarray platforms.
This review describes recent advances in several options of
microarray platforms used in glycoprotein analysis, including
glycoprotein arrays, glycan arrays, lectin arrays, and antibody/
lectin arrays. The translational use of these arrays in
applications related to characterization of cells and biomarker
discovery is also included. # 2010 Wiley Periodicals, Inc.,
Mass Spec Rev 29:830–844, 2010
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I. INTRODUCTION
Carbohydrates are molecules that have the ability to exist in
different isomeric forms that yield a variety of branching
structures. The complex structures that result from building
complex carbohydrates from simple sugars conjugate to a large
range of biological molecules such as lipids, proteins, and cell
surfaces which yield an array of biological selectivities. A glycan
chain can extend from a protein surface for a specific interaction
(Cyster, Shotton, & Williams, 1991), and without site-specific
glycosylations, many vital proteins would not be able to fold
properly (Helenius & Aebi, 2001). Glycosylated structures are
involved in a range of events such as development, immune
response, cell division, cancer cell camouflaging, pathogens
homing in on host cells, injury, and inflammation. Gene products
that participate in oligosacharride biosynthesis account for up to
1% of the translated genome. Of post-translational modifications
(PTMs), only phosphorylation occurs to a similar magnitude as
glycosylation. Glycosyltransferases and glycosidases in the
endoplasmic reticulum and Golgi apparatus produce glycopro-
teins of highly targeted structures. The location and amount of
sugar substitution is known to distinguish various cell types. For
example, cancer cells have been shown to use abnormal
glycosylation to evade detection by the immune system (Dennis
et al., 1987; Codington & Haavik, 1992). Acidity imparted to
glycan structures through sialic acid residues at the termini of
glycan structures also plays an important role in a glycoprotein’s
function. For example, the correct sialylation of N-linked
branched structures is essential for the activity of tissue
plasminogen activator (Geisow, 1992). Although glycosylation
is an abundant PTM, analysis of the structural variation of glycan
structures presents a challenging problem for analytical chem-
istry.
Many clinical biomarkers and therapeutic targets in cancer
are glycoproteins (Ferretti et al., 2007; Levitt & Slawin, 2007;
Hogdall, 2008) such as CA125 in ovarian cancer, Her2/neu in
breast cancer, and prostate-specific antigen (PSA) in prostate
cancer. The alteration in protein glycosylation, which occurs
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through varying the heterogeneity of glycosylation sites or
changing glycan structure of proteins on the cell surface and in
body fluids, has been shown to correlate with the development
and/or progression of cancer and other disease states (Arnold
et al., 2008; Ohyama, 2008; Zhao et al., 2008; Meany et al.,
2009). Identification of glycoprotein isoforms is becoming
increasingly important to the diagnosis and management of
human diseases, because several diseases result from glycan
structural alterations such as I-cell disease and congenital
disorders of glycosylation leukocyte adhesion deficiency type
II (Kościelak, 1995). An opinion article by Lebrilla and An
(2009) further details the potential of glycan markers for disease
diagnosis. In this article, the authors stated that the future holds
promise not only for disease diagnosis with glycan profiling but
also to aid the clinician to better understand disease progression
and disease strain identification.
The isolation and analysis of glycoproteins have followed a
similar path as the study of proteins in general. The number of
chromatographic and electrophoretic methods currently avail-
able has aided this work. Affinity chromatography has been of
particular importance to allow the isolation of glycoproteins with
the inherent affinity of glycan structures to lectins (Fang &
Zhang, 2008; Mechref, Madera, & Novotny, 2008). However, the
isolated proteins cannot be studied in their intact forms with
conventional X-ray crystallography methods. Furthermore,
isolated glycoproteins are often found as a mixture of different
glycoforms that are difficult to resolve. If resolved, the glyco-
forms are present at very low levels that require highly sensitive
detection technologies. A majority of studies have, therefore,
focused on fragmenting the glycoprotein into glycopeptides or
glycans and their corresponding proteins for further structural
determination (Robbe, Michalski, & Capon, 2006; Wuhrer et al.,
2007; Zhao et al., 2007a; Dalpathado & Desaire, 2008; Amon,
Zamfir, & Rizzi, 2008). Mass spectrometry and its continuous
development have facilitated structural elucidation of these
glycoproteins. The most important innovation has undoubtedly
been the introduction of ESI and MALDI together with new types
of mass analyzers that permit improved mass resolution and
accuracy for more confident structural assignments.
Glycoproteins arise when proteins conjugate to various
sugar chains (glycans) through amino acid residues. Linkage at
asparagines results in N-linked glycoproteins, whereas linkage at
serine or threonine results in O-linked glycoproteins. Although
these two forms of glycosylation are the most prominent, other
forms of glycosylation have been noted, such as glycation at
lysine residues observed in diabetes (Rajeswari et al., 1991).
N-linked glycans contain N-acetylglucosamine (GlcNAc) linked
to asparagines via an amide bond. In O-glycans, N-acetylga-
lactosamine (GalNAc) links the oligosaccharide’s reducing end
to the hydroxyl of the serine or threonine residue in the protein.
N-linked glycans possess a common core region of trimannosyl
chitobiose with two or three antennas extending from it. O-linked
glycans do not possess a core structure but comprise a number of
different regions with common motifs.
The extent of glycosylation in a protein usually depends on
the frequency of occurrence of asparagine, serine, and threonine
residues. Furthermore, any potential glycosylation site might or
might not be occupied with a variety of possible oligosacharride
structures. With this complexity in mind, the following
information would be required for the most comprehensive
picture of the glycoproteome: all glycosylated structures, the
carbohydrate sequence in these structures, the branching and
linkage in each of these sequences, as well as the site of
glycosylation.
This review presents some of the current methods for
glycoprotein analysis, with a particular focus on a more recently
developing technology, glycoprotein microarrays.
II. CHROMATOGRAPHIC METHODS
Chromatographic techniques have evolved considerably over the
past years. Together with diverse sample preparation techniques,
it is now possible to analyze a variety of sample types previously
almost impossible to comprehend. Complex samples such as
whole-cell proteins can now be enriched according to cellular
organelles (Castle, 2004; Gauthier & Lazure, 2008) or even
classes of compounds (e.g., phosphoproteins or glycoproteins),
to make it possible to zoom in on specific classes of molecules.
Lectin affinity chromatography is one such technique that
has facilitated glycoprotein studies. Lectins are proteins that
possess motifs that have a strong affinity for glycans (the sugar
component of glycoproteins). This interaction is strong enough to
exploit for isolation of glycoproteins. Many laboratories have
successfully employed this technique to characterize glycopro-
teomes (Lotan, 1979; Hirabayashi & Kasai, 2002; Hirabayashi,
2008a,b; Fang & Zhang, 2008; Mechref, Madera, & Novotny,
2008). Multi-lectin affinity chromatography (M-LAC), where
columns containing stationary phases bound to different lectins
with orthogonal affinities, have also been used in tandem to
further separate enriched glycoproteins (Yang & Hancock, 2005;
Plavina et al., 2007; Dayarathna, Hancock, & Hincapie, 2008).
More recently, a high-performance M-LAC material (HP-M-
LAC) has also been published with improved throughput and
recovery for glycoproteomics research (Kullolli, Hancock, &
Hincapie, 2008). Hydrophilic interaction chromatography
(HILIC) and graphitized carbon-based reverse-phase chroma-
tography have also been shown to profile glycan and glycopep-
tides at femtomole levels. Furthermore, the mobile phases in this
technique are compatible with mass spectrometry (Wuhrer,
de Boer, & Deelder, 2009). However, enrichment and liquid
chromatography alone do not provide all needed information
relative to glycoproteomes, because the separated glycoproteins
cannot be identified.
Mass spectrometry can be easily coupled to HPLC
techniques as long as favorable solvent systems are being
employed. This method has allowed very comprehensive and
detailed structural characterization of glycoproteomes. However,
an important factor to keep in mind in this case is that, to obtain
100% coverage with regard to protein structure, large quantities
of protein are often needed, which might not be feasible when
studying low-abundance proteins.
Two LC/MS-based approaches that have been employed to
study glycoproteins include profiling glycans released from their
glycoproteins and profiling glycopeptides from glycoprotein
digests. In glycan mapping, all sugar moieties from the
glycoprotein are first cleaved (typically using enzymatic
reactions using PNGase F), isolated, and analyzed with
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HPLC–MS. Normal-phase HPLC is usually employed for
separation due to the polar nature of the glycans being analyzed.
This approach can provide valuable information about overall
glycan structural changes that occur during disease progression
as the phenotype of the cell changes (Zhao et al., 2007a).
However, one pitfall of such a technique is that it does not provide
information on the protein origin of the glycan.
Profiling of glycopeptides, in contrast, is a site-specific
method. After enzymatic digestion of a glycoprotein with an
endoprotease, the resulting mixture of glycosylated and ungly-
cosylated peptides are analyzed with liquid chromatography
and mass spectrometry. Due to the high degree of heterogeneity
and the often high molecular weight of glycans, the mass
spectral signals of glycopeptides are much weaker than those of
unglycosylated peptides. Therefore, enrichment approaches are
often required. Graphitized carbon, cellulose, sepharose, and
lectins have been used as SPE materials for glycopeptide
enrichment (Wada et al., 2007; Zhang, Go, & Desaire, 2008).
To optimize the number of assigned peaks in the mass spectra, a
spectrum analysis and database search must be performed
manually for each eluting fraction, except several well-
characterized glycoproteins. If such an approach is employed
to study two different samples, then the presence or absence of
certain glycopeptide peaks can easily demonstrate differences
between the two samples. Though glycan structures and binding
sites of a glycoprotein can both be elucidated with glycopeptide
profiling, this technique is lower throughput. A rapid method of
analysis is still needed.
It is clear that solely LC–MS approaches to glycoprotein
analysis, although very comprehensive, often prove difficult.
Data analysis can become time consuming, and often a large
amount of sample is required for complete characterization.
Profiling complex mixtures of glycoproteins with the LC–MS
method alone is particularly cumbersome and leads to loss of
valuable information that is contained in lower abundance
proteins that might never be detected with LC–MS approaches.
A technique that is becoming increasingly popular involves
protein microarrays. Microarrays have proved to be a high-
throughput technique because they allow multiple analytes to be
investigated simultaneously due to their physical attachment to
unique regions on a single microarray slide that can be analyzed
with a reagent of choice (Tao, Chen, & Zhu, 2007; Uttamchan-
dani & Yao, 2008; Voduc, Kenney, & Nielsen, 2008). By taking
advantage of the high-throughput nature of the microarray
platform and exploiting the unique binding properties of
glycoproteins, carbohydrates, and glycans, comprehensive studies
of glycoproteomes are made possible. A variety of microarray-
based platforms for the study of glycoproteins have been pursued
thus far. Some of the platforms are discussed below.
III. MICROARRAY PLATFORMS FOR
GLYCOPROTEIN ANALYSIS
A. Carbohydrate Microarray
Carbohydrate microarrays have become a standard tool for
glycobiologists to screen large numbers of sugars and to
determine the role of carbohydrates in biological systems (de
Boer et al., 2007; Horlacher & Seeberger, 2008; Laurent,
Voglmeir, & Flitsch, 2008; Park, Lee, & Shin, 2008). The
potential applications of carbohydrate arrays are shown in
Figure 1. The carbohydrate can be either isolated from a natural
source or can be chemically synthesized. The low quantity and
the impurity of the isolated oligosaccharides limit their usage in a
chip-format study, whereas now the use of synthesized glycans is
dominating this field. A functional linker group required for
immobilization of sugars on a glass surface can be readily
incorporated in the synthesis process. A diversity of carbohydrate
structures that resembles the whole mammalian glycome can be
produced with fewer than 40 carbohydrate building blocks (Werz
et al., 2007).
A variety of glycan-type structures are arrayed on multiple
types of surface chemistries (e.g., nitrocellulose, glass, and
dextran) after which they are screened for binding. The most
general method for carbohydrate immobilization involves
covalent attachment of chemically modified carbohydrates onto
an N-hydroxysuccinimide (NHS)- or epoxide-containing surface
on a glass slide. Non-covalent, but site-specific, attachment
of carbohydrates on underivatized surfaces is also possible.
Interactions of different carbohydrate structures with a wide
variety of biological targets, including proteins, RNA, viruses,
and whole cells, have been investigated with this technique. This
approach has been used to profile carbohydrate-binding proteins,
the characterization of carbohydrate–cell recognition, as well as
the detection of specific antibodies for the diagnosis of diseases
(Dotan et al., 2006).
Glycan-microarray technology has been used to assess the
virus-receptor specificity of influenza viruses based on the
species-specific nature of the interaction between the virus
and host glycans (Stevens et al., 2006). Recently, Ratner and
Seeberger (2007) and Adams et al. (2004) have prepared
carbohydrate slides to identify human immunodeficiency virus
(HIV) vaccine candidate antigens, to detect pathogenic bacteria,
and to determine the binding profile of heparin-binding proteins.
With photogenerated glycan arrays, an immunogenic sugar
moiety has been detected on the exosporium of anthrax spores for
the development of a targeting vaccine (Wang et al., 2007). A
neoglycolipid technology has been invented for microarray
analysis of glycans (Feizi & Childs, 1994; Feizi et al., 1994; Liu
et al., 2007). The advantage of neoglycolipids is that they can be
readily immobilized by hydrophobic force on the chemical
surface. These glycans can react with lectins, anti-glycan
monoclonal antibodies or carbohydrate-binding cytokines, or
chemokines.
The utility of labeling methods for glycan array detection
with fluorescence-tagged molecules has been limited by
denaturation of protein and availability of secondary reagents.
To overcome this problem, label-free detection techniques
such as surface plasmon resonance (Nelson et al., 2001) and
MALDI-TOF (Su and Mrksich, 2002) have been used to
monitor the protein–glycan interaction or carbohydrate-process-
ing enzyme activity after the glycans are immobilized to a gold
surface via the disulfide bond. In an application of using glycan
array with MALDI-TOF–MS to study the GalTase-mediated
galactosylation, mass spectra gave explicit information about
the change of the sugar chain structure after glycan array
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presenting b-GlcNAc were incubated with the enzyme (Su and
Mrksich, 2002).
B. Lectin Arrays
Although carbohydrate arrays yield valuable information about
carbohydrate-interacting proteins, they do not allow one to
directly examine changes in glycosylation. Alterations in
carbohydrate structure of glycoproteins are known to be related
to cellular regulation and tumor growth. Other technologies
available for glycan analysis, such as chromatography and mass
spectrometry, tend to be time consuming and less suitable for
high-throughput evaluation of protein glycosylation. Although
detailed information on glycan structures might be obtained with
mass spectrometry, data analysis is complex and time consuming.
The lectin array employs the same architecture as the glycan
microarray (Fig. 2). There has been increased interest in the use
of lectins in an array format (Nagaraj et al., 2008). Current studies
with lectin arrays have focused on assessing the specificity of
lectin binding to carbohydrates. Lectin arrays determine the most
appropriate lectins for glycoprotein enrichment as well as for
the removal of undesirable glycoproteins. Lectin microarrays
could also be used for rapid and simple analysis of protein
glycosylation, although they will not detect all glycans in a
complex sample, nor will they provide complete structure
assignment. This technology is based on binding of an intact
glycoprotein or glycopeptides to the arrayed lectins, to provide a
characteristic fingerprint pattern that is highly sensitive to
changes in a protein’s glycan composition. Hsu and Mahal
(2006) have described a lectin-array protocol for high-throughput
evaluation of cell-surface microbial sugars. The binding patterns
of fluorescent bacteria to these arrays provided a simple means to
fingerprint bacteria based on their surface carbohydrates. A
beneficial aspect of lectin arrays is that the large number of
lectins, each with their specific recognition pattern, provides a
high level of sensitivity to changes in the glycosylation pattern.
Kuno et al. (2005) and Uchiyama et al. (2006) developed a lectin-
microarray procedure based on an evanescent-field fluorescence
detection principle that allowed a sensitive, real-time observation
of multiple lectin–carbohydrate interactions. This method
allows quantitative detection of even weak lectin–carbohydrate
interactions. Fully specific signal patterns for various Cy3-
labeled glycoproteins, glycopeptides, and tetramethylrhod-
amine-labeled oligosaccharides were detected with this platform.
Lee et al. (2008) have successfully used lectin arrays together
with LC–ESI–MS/MS to distinguish between endothelial and
fibroblast cells. In their study, nine different lectins were used to
characterize cell-surface glycoproteins that would distinguish
between the two different types of cells. Six potential candidate
surface proteins were identified that could distinguish these cells.
A similar study was also done by the same group to distinguish
normal and cancerous breast cells based on differential cellular
surface glycoproteins (Chen et al., 2007b). Tao et al. (2008) used
lectin arrays to study cellular development and differentiation.
They used lectin arrays to show mannose-dependent tropisms
FIGURE 1. Application range of carbohydrate-microarray experiments. The carbohydrate– ligand
specificity for carbohydrate-binding molecules has been assessed. Screening for inhibitors of
carbohydrate-mediated interactions and determination of IC50 values can be performed by a co-incubation
of the binding molecule with an inhibitor. Sugar interactions of an entire organism such as a whole cell or
virus can be determined without purifying the carbohydrate-binding proteins. Reprinted and adapted with
permission from Horlacher and Seeberger (2008). Copyright 2008, Royal Society Chemistry.
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with a model pathogen, as well as novel lectin biomarkers for
cancer stem-like cells in a murine model. One problem with
any microarray approach is often the small amount of probes
that are found naturally. The cost of the probe is particularly
notable when the probe is serum or other biological fluid that is
often not available in abundant amounts. Slide processing,
therefore, must be done with care to ensure that minimal
amounts of the probes are used for an analysis. Nagaraj et al.
(2008) have recently developed a protocol that uses piezo-
electric printing to deposit sample directly onto the lectin spot
on an array. This method circumvents the conventional slide-
hybridization process, where a slide is washed in a larger
volume of probe. Instead, nanoliter amounts of probe are
directly deposited onto the lectin spot with non-contact
piezoelectric means. The functionality and utility of such a
protocol was demonstrated by distinguishing closely related
isoforms of fetuin using this technique.
Although lectin arrays and carbohydrate arrays provide
valuable information about carbohydrate-interacting proteins
and lectin–glycoprotein interaction, they do not allow one to
screen whole glycoproteomes to study changes in an individual
protein’s glycan expression within that glycoproteome and
changes in overall glycoprotein patterns.
C. Glycoprotein Microarrays
Protein microarrays are a useful screening method for whole-cell
lysates, fractionated proteomes, intact glycoproteins, and antigen–
antibody reactions (Tao, Chen, & Zhu, 2007; Kricka & Master,
2008). Unlike oligonucleotides, proteins are broadly heteroge-
neous in size, shape, and chemistry. To maximize the quality of
data obtained, choosing the surface with the best signal-to-noise
ratio is critical. Glass-coated surfaces with specific chemical
functionalities are very popular because they eliminate back-
ground fluorescence. Deposition of proteins on the surface, such
as an epoxide-coated surface, results in covalent linkage to the
glass. Nitrocellulose slides are among the most popular
substrates due to their low cost. The ultrathin nitrocellulose
FIGURE 2. Analysis of cellular glycomes, using lectin and antibody arrays. The arrays were generated by
immobilization of lectins and glycan-specific antibodies on a chip. Glycoproteins from cell or tissue samples
were labeled with a fluorescent dye and incubated with the array. The fluorescent spots reflect the presence of
glycoproteins that bear glycans recognized by the corresponding lectin or antibody. The technique
provides minimal structural detail, but permits rapid high-throughput analysis of many samples. Intact cells
or virus particles can also be interrogated on lectin microarrays. Reprinted and adapted with permission
from Bertozzi and Sasisekharan (2009). Copyright 2009 by The Consortium of Glycobiology Editors,
La Jolla, California.
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layer provides a lower fluorescence background while maintain-
ing good binding capacity. Sprenger and co-workers developed
thin film-coated photoactivatable surfaces (dextran-coated glass
slides) suitable for covalent immobilization of glycans, glyco-
conjugates, and lectins in microarray formats (Angeloni et al.,
2005). In this work, standard glycoproteins were covalently
immobilized, and exposed glycans were successfully profiled
with lectins for fucose, sialic acid, and galactose. These platforms
were also suitable for glycans and lectin immobilization which
allowed for biomolecule binding to such microarray platforms
and illustrated the versatility of the microarray-based tools with
different applications.
One very promising strategy that has been explored is the use
of multidimensional-fractionation techniques to simplify cell
lysates into less-complex fractions to produce natural protein
microarrays (Taylor et al., 2008). Briefly, cellular proteins from a
cancer cell line are first resolved with a pI-based fractionation
with chromatofocusing or isoelectric focusing. Each fraction is
separated further with reversed-phase HPLC. The fractionated
proteins are lyophilized, re-suspended in a suitable buffer, and
printed on a nitrocellulose-based microarray. The protein
microarray is screened with sera or modification-specific
detection reagent. This technique has been used by our group
to study the humoral response and to identify potential serum
biomarkers for prostate cancer. It is shown that specific fractions
are immunoreactive against prostate cancer serum but not against
serum from healthy individuals.
Based on the natural protein microarray approach, recently
a method for global analysis of glycosylation patterns and
detection of glycosylation alterations in cancer serum was
developed (Patwa et al., 2006). This strategy uses an all-liquid-
phase enrichment and prefractionation methodology coupled to
glycoprotein microarray technology, using a multiple lectin-
based, biotin–streptavidin detection scheme. Selective detection
of glycan structures was made possible by employing multiple
lectins to screen glycoproteins from serum samples from normal
subjects or patients with chronic pancreatitis or pancreatic
cancer. The general strategy is shown in Figure 3, where a
FIGURE 3. Proposed experimental strategy to study serum glycoproteins. (1) Lectin purification with a
general lectin column. (2) Non-porous reversed-phase HPLC separation and fraction collection. (3)
Microarray production with a non-contact piezoelectric printing device. (4) Glycan detection with
biotinylated lectin–streptavidin–Alexafluor555. (5) Image acquisition and spot analysis with Genepix 6.0
software. Reprinted with permission from Patwa et al. (2006). Copyright 2006, American Chemical Society.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
GLYCOPROTEIN ARRAYS &
Mass Spectrometry Reviews DOI 10.1002/mas 835
complex serum sample was first depleted of the top 12 most
abundant proteins in human serum with an antibody column to
detect low-abundance proteins. Glycoproteins were subse-
quently enriched from depleted fractions with a dual-lectin
column that contained lectin ConA and WGA. ConA recognizes
N-linked mannose, including high-mannose-type and mannose
core structures, and WGA recognizes terminal GlcNAc. Using
these two lectins with broad specificities, most of the glyco-
proteins could be isolated. The glycoprotein pool was further
fractionated with 1-D or 2-D liquid-phase separation, such as
isoelectric focusing, coupled with reversed-phase HPLC. The
purified glycoproteins were spotted onto nitrocellulose slides and
were probed with five different biotinylated lectins followed
by streptavidin conjugated to a fluorescent tag. Both maackia
amurensis lectin (MAL) and sambucus nigra lectin (SNA)
recognize sialic acid on the terminal branches. SNA binds
preferentially to sialic acid attached to terminal galactose in an
(a-2,6) and, to a lesser degree, an (a-2,3) linkage. MAL detects
glycans that contain NeuAc–Gal–GlcNac with sialic acid at
the 3-position of galactose. Peanut agglutinin (PNA) binds
de-sialylated exposed galactosyl (b-1,3) GalNAc, and aleuria
aurantia lectin (AAL) recognizes fucose linked (a-1,6) to
GlcNAc or (a-1,3) to N-acetyllactosamine. These five lectins
covered a majority of N-glycan types and differentiated them
according to their specific structures. The printed glycoproteins
were incubated with biotinylated lectins, and the bound
biotinylated lectins were detected with streptavidin conjugated
to AlexaFluor555. This sandwich-type detection scheme was
employed because the very specific biotin–streptavidin inter-
action improved signal-to-noise ratios.
The specificity, reproducibility, and sensitivity of such an
approach were tested with five standard glycoproteins: fetuin,
asialofetuin, thyroglobulin, ribonuclease B, and transferrin. The
images obtained when slides were probed with each of the lectins
are shown in Figure 4. These data correlated well with previously
reported glycan structures that correspond to the standard
glycoproteins used in this study. The difference in the glycan
structures can be readily distinguished. The use of lectins for
FIGURE 4. Scanned images of printed standard glycoproteins probed with different lectins. Each block
bracketed on the right represents a dilution series of standards from 0.025 to 0.5 mg/mL. Each dilution has
been printed as nine replicates in a 3 3 block. Reprinted with permission from Patwa et al. (2006).
Copyright 2006, American Chemical Society. [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
FIGURE 5. Detection of glycans on antibody arrays. The first step of this new method is the chemical
derivatization of the glycans on the spotted antibodies to block lectin binding to those glycans. The cis-
hydroxyl groups of the glycans on the spotted antibodies were gently oxidized to convert them to aldehyde
groups, which react with a hydrazide–maleimide bifunctional cross-linking reagent; the resulting product
reacts with a Cys–Gly dipeptide. The Cys–Gly dipeptide adds bulk to the derivatized carbohydrates to
hinder lectin binding. Reprinted and adapted with permission from Chen et al. (2007). Copyright 2007,
Nature Publishing Group. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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glycan structure detection enables the measurement of several
glycoforms of each individual glycoprotein (e.g., sialylated and
non-sialylated glycoforms can be distinguished with SNA). The
sensitivity of this approach was approximately 5 fmol, and the
variance was within 10% as determined by nine replicate spotting
events for each standard protein.
Due to the complexity of some samples and limited
resolution of RP-HPLC fractionation, the accuracy of the
biomarker candidates identified with the glycoprotein microarray
might be compromised when the differentiated fraction contains
several glycoproteins and none of them is dominant. In this case
the protein that contributes the most to the observed lectin
binding cannot be determined. Normalization of the amount of
the glycoprotein using the UV peak area can be also problematic.
Follow-up experiments, such as antibody array and lectin blot,
are necessary to test the validity of the finding. In terms of future
developments for the glycoprotein microarray, we are looking
forward to more different types of separations coupled with the
FIGURE 6. The MALDI–MS spectra generated from the microarray spots of amyloid p component
antibody after on-target digestion. The peaks identified as amyloid p component were marked with green
arrows, where the extra peaks that appear in (c) were marked with black arrows. a: Control spot, without
incubation with serum; (b) incubated with10 diluted serum; (c) incubated with 2 diluted serum.
Reprinted and adapted with permission from Li et al. (2009). Copyright 2009, American Chemical Society.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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microarray platform for improved fractionation especially for
glycoforms.
D. Antibody Microarrays
The use of antibodies is a means to capture and purify specific
proteins in a natural state. The antibody microarray allows the
efficient, multiplexed study of multiple individual proteins from
complex mixtures (Borrebaeck & Wingren, 2007; Korf et al.,
2008). The variable carbohydrate structures attached to the
captured proteins can be characterized by studying the interaction
between the glycans and different kinds of biotinylated lectins or
glycan-binding antibodies. However, this application had been
limited by the lectin-binding glycans that attach on the antibody
itself. Gornik and Lauc (2007) and Chen et al. (2007a) have
developed similar methods to chemically block the glycans on
the antibody. Both groups treated the antibodies with sodium
periodate to oxidize the cis-hydroxyl groups on the glycans
into aldehyde groups, whereas Chen et al. (2007a) further
sequentially modified the resulting product with a hydrazide–
maleimide cross-linking reagent and a dipeptide (Fig. 5). They
also demonstrated selective binding of lectins toward glycoforms
generated by deriving the sample with neuraminidase which
removes terminal sialic acid groups. Profiling protein and glycan
variation in multiple samples with parallel-sandwich and
glycan-detection assays showed cancer-associated glycan alter-
ation on the proteins MUC1, MUC5AC, and MUC16 in
pancreatic cancer cell lines stimulated by pro-inflammatory
factors (Wu et al., 2008). In addition, the author suggested that
inflammation might influence the cells in a specific cell-type
manner because the cell lines bearing minimal or multiple
markers exhibited opposite responses. Another study on serum
detection of pancreatic cancer with antibody microarrays was
performed to validate biomarker candidates found in previous
studies (Li et al., 2009). A 67% increased response to lectin
SNA was found on alpha-1-beta glycoprotein in the serum of
pancreatic cancer patients compared to the serum of patients with
chronic pancreatitis and normal controls. The results were
provided by statistical analysis of the data collected from 183
samples to ensure reproducibility. In addition to the fabrication of
an antibody array on glass slides, there is an alternate format,
which is crafted by depositing antibodies into individual wells
on a multiple-well plate. Meany et al. (2009) investigated the
glycosylation of PSA and found that the alteration of the glycan
structure of the PSA was more relevant to the progression of
prostate cancer. An antibody-assisted lectin-profiling (ALP)
platform has also been evaluated by Kuno et al. (2009). In this
approach, a glycoprotein of interest was first enriched from a
medium with an antibody. The glycoprotein was quantified with
FIGURE 7. Sections of glycoprotein microarray to compare one fraction from NPS-RP-HPLC across all 24
samples. Each panel is a section of identical arrays probed with lectin indicated on the left side of the panel. It
was observed that this fraction contained proteins that were predominantly mannosylated and fucosylated. It
was also observed that the level of glycosylation (based on raw microarray data) was higher in cancer
samples compared to the controls. Reprinted with permission from Zhao et al. (2007b). Copyright 2007,
American Chemical Society. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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blotting experiments, and lectin profiling of the protein was
performed. This approach revealed disease- and tissue-specific
glycosylation changes in model systems of PSA and podoplanin
at picomole levels.
In addition to detection with lectin- and glycan-binding
antibody strategies, mass spectrometry can potentially play an
important role to read microarrays. Evans-Nguyen et al. (2008)
prepared antibody microarrays, which capture peptides from a
simple mixture on gold- and polymer-modified glass slides and
performed MALDI–MS by accurately depositing matrix onto
antibody spots with a microarray printer. Other work includes an
on-slide digestion technique, which has been developed to
analyze the glycoproteins captured by the antibody array with
MALDI–MS (Li et al., 2009). After the slides are hybridized
with serum, an appropriate volume of trypsin solution was
printed onto the antibody spots, and the slides were kept in a
humidified chamber for 3 min before the matrix was applied to
the spots. Although the enzyme digested the captured glyco-
proteins and the antibody, the antibody peaks could be excluded
by adding a blank block on the slides (see Fig. 6). This on-slide
digestion technique identified several target glycoproteins for the
antibodies from serum by MALDI–MS/MS. The identities of
the glycoproteins proved the specificity of the antibodies when
they were incubated with properly diluted serum.
Antibody– lectin sandwich microarray provides a means to
measure glycosylation change on specific proteins captured from
complex samples with lectin probes in a high-throughput array
format. Compared to HPLC–MS, it is not only a simple and
reproducible way of investigating a large number of samples
but also a type of assay that analyzes proteins in their native
form which can be crucial for understanding the functional
role of glycoproteins in the biological environment. Although
the antibody–lectin sandwich microarray platform is able to
distinguish glycoforms with different glycan structures, the use
of fluorescence provides less detailed structural information than
MS/MS. The introduction of mass spectrometry-based label-free
detection would provide a means for further characterization of
the glycan structure. It should be noted that insufficient blocking
FIGURE 8. The normalized glycoprotein microarray responses to lectin AAL were visualized with
principal component analysis (PCA). Twenty-four serum samples (10 normal, 8 chronic pancreatitis, and 6
pancreatic cancers) were studied. The figure shows the clustering of serum samples obtained from patients
with pancreatic cancer, chronic pancreatitis, or normal subjects. Reprinted with permission from Zhao et al.
(2007b). Copyright 2007, American Chemical Society.
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efficiency with some of the lectins such as ConA limits the
detection of several interesting glycan structures. To reduce the
noise or background, we are searching for other chemical
blocking strategies and even other platforms for the next
generation of antibody–lectin assays.
E. Glycoprotein Microarray Applications
The glycoprotein microarray method has been applied to the
glycosylation profiling of pancreatic cancer, colon cancer, and
esophageal cancer sera (Zhao et al., 2007b; Qiu et al., 2008).
A scanned image of one HPLC fraction from 10 normal, 8
pancreatitis, and 6 pancreatic cancer serum samples detected by
the five lectins is shown in Figure 7. The normalized glycoprotein
microarray responses to lectins were visualized by principal
component analysis (PCA). The response to lectin AAL, which
binds to fucosylation sites, generally distinguished the three
clinical groups (Fig. 8). Pancreatic cancer samples clustered
farther away from normal compared to chronic pancreatitis,
especially in response to fucosylation and sialylation. Altered
glycosylation patterns have also been observed in individual
proteins, such as hemopexin, antithrombin-III, and kininogen-1
in pancreatic cancer sera. One of the advantages of this approach
is that the differential response can be tracked back to the original
fraction from which the spot was created. A combination
of chromatographic separation, mass spectrometry, and other
characterization techniques can be used to analyze and define the
target glycome. In this approach, the altered glycosylation was
determined with a combination of Western blotting and mass
spectrometry. The results from peptide mapping and Western
blotting experiments confirmed the observations made in the
glycoprotein microarray experiments. For example, elevated
sialylation on one glycosylation site was detected on haptoglo-
bin-related protein with peptide mass mapping, and increased
fucosylation was also detected with the lectin-blotting experi-
ment. These results were consistent with the array study, where
over-expressed fucosylation and sialylation were both observed
in pancreatic cancer serum.
A study similar to the one described above determined
specific glycosylation changes that might occur as a function of
the development of colorectal cancer and esophageal cancers
(Qiu et al., 2008). Glycoproteins were isolated from sera of
healthy individuals and patients with colonic adenomas or
colorectal and esophageal cancers. Separation by LC followed by
microarray generation and hybridization together with statistical
treatment of all data elucidated some key proteins that might be
involved in cancer development. An additional piece of research
that was done in these studies involved confirmation of the
glycosylation sites in the glycoprotein of interest and an
unblinded validation with independent samples from each class
FIGURE 9. Elevated fucosylation and sialylation of complement C3 (A) and histidine-rich glycoprotein
(C) investigated with AAL and SNA blot analysis. The corresponding protein expression levels are shown in
(B) for complement C3 and (D) for histidine-rich glycoprotein, respectively. Reprinted with permission
from from Qiu et al. (2008). Copyright 2008, American Chemical Society. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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of human sera studied. Glycoproteins that were unique to a
specific class of sera were isolated from all validation sera with
HPLC, and a lectin blot validated the glycosylation levels of
those proteins. Results confirmed those results obtained with the
glycoprotein microarray approach (Fig. 9). A similar approach is
currently used to analyze glycosylation changes present during
the development of diabetes.
Protein glycosylation screening analysis might allow for the
detection of alterations in protein glycosylation in samples from
patients with different clinical conditions. Not only alterations in
absolute protein levels, but importantly, changes in PTM on the
protein, such as glycosylation, could indicate the presence,
absence, or severity of a disease. The ability to rapidly and
sensitively screen protein glycosylation patterns and detect
glycosylation alterations might provide a potentially efficient
means to screen patients for cancer, such as pancreatic cancer and
possibly other cancers.
IV. CONCLUSION
There is a dramatic increase in the number of publications that
use microarray technology. Increased advances are also being
made in other technologies that could potentially be used
together with microarray technologies, especially the integration
of mass spectrometry as a label-free detection method in glycan
and antibody array techniques. Protein glycosylation analysis
with protein microarrays has proven to be a high throughput and
successful technique that not only provides a high level of
information about glycoprotein abundance changes but also
sheds light on more specific glycan-associated changes respon-
sible for disease progression or disease presence. Combining this
technology with advancing complementary techniques such
as affinity enrichment, sample depletion to eliminate high-
abundance proteins, and mass spectrometry has great potential to
further utilize microarray technology to aid in diagnosis or
management of human disease.
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